博瑞医药终止向实控人不超5亿定增 民生证券保荐折戟

Core Viewpoint - 博瑞医药 has decided to terminate its plan for a specific issuance of A-shares for 2024 and has withdrawn the application documents, citing current market conditions and the company's actual situation as the main reasons for this decision [1][2]. Group 1: Termination of A-share Issuance - 博瑞医药 announced the termination of its plan to issue A-shares to specific investors and has applied to the Shanghai Stock Exchange to withdraw the related documents [1]. - The decision was made after careful consideration of the current market environment and the company's development plans, aiming to protect the interests of all shareholders, especially minority investors [2][3]. Group 2: Financial Implications - The planned issuance aimed to raise up to 500 million yuan, with the net proceeds intended for working capital and repayment of bank loans [2]. - The issuance was to be conducted at a price of 22.36 yuan per share, with the main underwriter being Minsheng Securities [2]. Group 3: Shareholder Structure - As of the date of the fundraising prospectus, major shareholders holding 5% or more of the company included 袁建栋 and 博瑞咨询, with 袁建栋 being the controlling shareholder [3]. - 袁建栋 directly holds 26.86% of the shares, while his mother, 钟伟芳, holds 5.33%, and together they control 38.53% of the voting rights [3]. Group 4: Previous Fundraising Activities - 博瑞医药 has raised a total of 1.213 billion yuan through three fundraising activities since its A-share listing nearly six years ago [4]. - The company went public on November 8, 2019, raising approximately 521.11 million yuan, with net proceeds of about 439.98 million yuan [4].